Joint Formulary & PAD

Semaglutide - Prevention of cardiovascular events

You are here : Home > Formulary Search > Semaglutide - Prevention of cardiovascular events

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green
Formulations :
  • Injection
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
NICE
SPC
Restrictions / Comments :
Important

Please prescribe by brand - WEGOVY only - for eligible cohorts see here > NICE TA1152 

Documents :
 
NICE Technology Appraisal
NICE TA1152 Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity

Documentation

Information
GLP-1 medicines for weight loss and diabetes: what you need to know - MHRA guidance

PAD Profile

ChemicalSubstance :
Semaglutide
Indication :
Prevention of cardiovascular events
Group Name :
Keywords :
obesity, overweight, cardiovascular disease, CVD
Brand Names Include :
Wegovy
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
2

Committee Recommendations (0)

  • No records returned.

Other Indications

Below are listed other indications that Semaglutide is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Prevention of cardiovascular events.

  • No records returned.